Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis

Recruiting now · Phase 1

Conditions studied: Lupus Nephritis (LN)

In brief

This study is researching a particular group of experimental drugs administered for a short period in the treatment of participants with Lupus Nephritis (LN). The main aim of the current study is to see how safe and tolerable the study drugs are in a long-term follow-up. This is a main study, called an umbrella study, which includes several independent smaller sub-studies. Each of these smaller main sub-studies tests different drugs at the same time, all aimed at treating LN. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)

Key facts

Study ID
NCT06975787
Run by
Regeneron Pharmaceuticals
People needed
90
Starts
2025-12-22
Expected to finish
2029-09-09
Last updated by the study team
2026-07-09

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.